EUVIMEDEUVIMED entdecken
Open Access

Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A

Kosei Ishimaru iD, Masataka Ikeda iD, Hiroko Deguchi Miyamoto iD, Shun Furusawa iD, Ko Abe iD, Masatsugu Watanabe, Takuya Kanamura, Satoshi Fujita, Ryohei Nishimura, Takayuki Toyohara, Shouji Matsushima iD, Tomoko Koumura und 4 weitere

Journal of the American Heart Association · 02.01.2024 · 13 (1)

DOI: 10.1161/jaha.123.031219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 02.01.2024. Verfasst von Kosei Ishimaru und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Faculty of Medical Sciences Kyushu University Fukuoka Japan. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, Ferroptosis, Myocardial Infarction, Reperfusion Injury. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ferroptosis, an iron‐dependent form of regulated cell death, is a major cell death mode in myocardial ischemia reperfusion (I/R) injury, along with mitochondrial permeability transition‐driven necrosis, which is inhibited by cyclosporine A (CsA). However, therapeutics targeting ferroptosis during myocardial I/R injury have not yet been developed. Hence, we aimed to investigate the therapeutic efficacy of deferasirox, an iron chelator, against hypoxia/reoxygenation‐induced ferroptosis in cultured cardiomyocytes and myocardial I/R injury. Methods and Results The effects of deferasirox on hypoxia/reoxygenation‐induced iron overload in the endoplasmic reticulum, lipid peroxidation, and ferroptosis were examined in cultured cardiomyocytes. In a mouse model of I/R injury, the infarct size and adverse cardiac remodeling were examined after treatment with deferasirox, CsA, or both in combination. Deferasirox suppressed hypoxia‐ or hypoxia/reoxygenation‐induced iron overload in the endoplasmic reticulum, lipid peroxidation, and ferroptosis in cultured cardiomyocytes. Deferasirox treatment reduced iron levels in the endoplasmic reticulum and prevented increases in lipid peroxidation and ferroptosis in the I/R‐injured myocardium 24 hours after I/R. Deferasirox and CsA independently reduced the infarct size after I/R injury to a similar degree, and combination therapy with deferasirox and CsA synergistically reduced the infarct size (infarct area/area at risk; control treatment: 64±2%; deferasirox treatment: 48±3%; CsA treatment: 48±4%; deferasirox+CsA treatment: 37±3%), thereby ameliorating adverse cardiac remodeling on day 14 after I/R.

Conclusions

Combination therapy with deferasirox and CsA may be a clinically feasible and effective therapeutic approach for limiting I/R injury and ameliorating adverse cardiac remodeling after myocardial infarction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial Reperfusion InjuryFerroptosisMyocardial InfarctionReperfusion InjuryIron OverloadMyocardial IschemiaMiceAnimalsCyclosporineDeferasiroxVentricular RemodelingMyocytes, CardiacIronHypoxia

Stichwörter der Autor:innen

cyclosporin Adeferasiroxferroptosisischemia reperfusion injury

Substanzen

CyclosporineDeferasiroxIron

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Faculty of Medical Sciences Kyushu University Fukuoka Japan.
  • Division of Cardiovascular Medicine, Research Institute of Angiocardiology, Faculty of Medical Sciences Kyushu University Fukuoka Japan.
  • Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical Sciences Kyushu University Fukuoka Japan.
  • Department of Hygienic Chemistry and Medical Research Laboratories, School of Pharmaceutical Sciences Kitasato University Tokyo Japan.
  • Department of Molecular Pathobiology, Faculty of Pharmaceutical Sciences Kyushu University Fukuoka Japan.
  • School of Medicine and Graduate School International University of Health and Welfare Fukuoka Japan.

ORCID-Profile: Kosei Ishimaru, Masataka Ikeda, Hiroko Deguchi Miyamoto, Shun Furusawa, Ko Abe, Shouji Matsushima, Ken-Ichi Yamada, Tomomi Ide

Zitieren

APA

Ishimaru, K., Ikeda, M., Miyamoto, H. D., Furusawa, S., Abe, K., Watanabe, M., Kanamura, T., Fujita, S., Nishimura, R., Toyohara, T., Matsushima, S., Koumura, T., Yamada, K. I., Imai, H., Tsutsui, H., & Ide, T. (2024). Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A. Journal of the American Heart Association, 13(1). https://doi.org/10.1161/jaha.123.031219

Vancouver

Ishimaru K, Ikeda M, Miyamoto HD, Furusawa S, Abe K, Watanabe M, et al. Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A. Journal of the American Heart Association. 2024;13(1). doi:10.1161/jaha.123.031219

BibTeX
@article{Ishimaru2024,
  author = {Ishimaru, Kosei and Ikeda, Masataka and Miyamoto, Hiroko Deguchi and Furusawa, Shun and Abe, Ko and Watanabe, Masatsugu and Kanamura, Takuya and Fujita, Satoshi and Nishimura, Ryohei and Toyohara, Takayuki and Matsushima, Shouji and Koumura, Tomoko and Yamada, Ken-Ichi and Imai, Hirotaka and Tsutsui, Hiroyuki and Ide, Tomomi},
  title = {Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {1},
  doi = {10.1161/jaha.123.031219}
}
Kostenlos starten →